Concenter BioPharma Overview
Concenter BioPharma develops drugs for treating and preventing type 2 diabetes. The company has developed a family of nonsteroidal chemical complexes made from components approved for clinical use. These new chemical entities constitute a protected platform of drugs with proven efficacy and safety. The members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications. Concenter BioPharma is a subsidiary of Silkim Pharma.
Cumulative Funding Raised Over Time ($)
$2.0MMay 2016
$3.2MSep 2020
Latest News
growth-positive
סטארטאפ ישראלי מפתח תרופה לסוכרת סוג 2
Israeli biotech company Concenter BioPharma is developing a drug that could potentially cure type 2 diabetes. The company has begun raising funds for clinical trials and expects the drug to be on the market within three years. Concenter BioPharma is currently nearing the end of a funding round of 4 million shekels on the Pipelbiz crowd investing platform to finance clinical trials at the end of 2020. The FDA has approved a shortened regulatory process for the drugs approval, which is expected to reach the market within three years.
Investment
growth-positive
Finally, a pill that could fix the root cause of diabetes
Concenter BioPharma, an Israeli company, is developing a drug called Zygosid-50 that aims to restore near-normal cellular sensitivity to insulin in type 2 diabetes patients. The drug has shown promising results in animal trials, reducing insulin resistance and normalizing diabetes-associated parameters. Concenter BioPharma is raising funds for clinical trials approved by the FDA and plans to conduct phase 1 and phase 2a trials in Israel. The company is self-funded but will launch a $5 million funding round for its activities in 2020. Diabetes affects a large number of people globally, and the estimated cost of treating diabetes per year is over $850 billion. Concenter BioPharma aims to develop a drug that treats insulin resistance without side effects.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.18M |
| Last funding | $1.18M |
| Stage | A |
| Rounds | 2 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.concenterbiopharma.com |
Locations
Israel
Photos & Videos
2 item(s)
Concenter BioPharma Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsCore Technology
BiologicalsTags (10)
biopharmaceuticalbiotechnologyinflammatory-diseasespharma-companiesoral-drugsdrug-discoverydiabetespharmaceuticalsdrug-developmenttype-2-diabetesGeographic Markets
United StatesAsiaEuropeConcenter BioPharma Financials
$3.18M
Total funding
Undisclosed
Capital raised
$1.18M
Last funding
A
Funding stage
2
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$2.0MMay 2016
$3.2MSep 2020
Private Equity Funding
Equity crowdfunding
Sep 2020
$1.18M
PipelBiz
A Round
May 2016
$2M
Concenter BioPharma Lifecycle
Cumulative Funding Raised Over Time
$2.0MMay 2016
$3.2MSep 2020
All Events
Equity crowdfunding
Sep 2020
$1.18M
PipelBiz
A Round
May 2016
$2M
Concenter BioPharma News
2 articles
growth-positive
סטארטאפ ישראלי מפתח תרופה לסוכרת סוג 2
Israeli biotech company Concenter BioPharma is developing a drug that could potentially cure type 2 diabetes. The company has begun raising funds for clinical trials and expects the drug to be on the market within three years. Concenter BioPharma is currently nearing the end of a funding round of 4 million shekels on the Pipelbiz crowd investing platform to finance clinical trials at the end of 2020. The FDA has approved a shortened regulatory process for the drugs approval, which is expected to reach the market within three years.
Investment
growth-positive
Finally, a pill that could fix the root cause of diabetes
Concenter BioPharma, an Israeli company, is developing a drug called Zygosid-50 that aims to restore near-normal cellular sensitivity to insulin in type 2 diabetes patients. The drug has shown promising results in animal trials, reducing insulin resistance and normalizing diabetes-associated parameters. Concenter BioPharma is raising funds for clinical trials approved by the FDA and plans to conduct phase 1 and phase 2a trials in Israel. The company is self-funded but will launch a $5 million funding round for its activities in 2020. Diabetes affects a large number of people globally, and the estimated cost of treating diabetes per year is over $850 billion. Concenter BioPharma aims to develop a drug that treats insulin resistance without side effects.
Investment
Concenter BioPharma Team
Prof. Mordechai (Mottie) Chevion
Co-founder & CSO
Founder
Employee Info
| Employees (range) | 1-10 |
| Exact count | 3 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Concenter BioPharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | founding month, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516018678 |
| Crunchbase | concenter-biopharma-silkim-ltd |
| Creator | Dror Chevion |
| Creator email | dror@chevion.biz |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wain@gmail.com |
| Last update | 2020-10-19T00:00:00.000Z |
| Created | 2015-10-13T00:00:00.000Z |
| Claimed | Yes |